(Q37316991)

19 August 2017

1 reference

title

Association between response to primary treatments and MGMT status in glioblastoma (English)

1 reference

19 August 2017

Enrico Franceschi

1

0 references

Alba A. Brandes

object named as

Alba A Brandes

series ordinal

4

0 references

author name string

Alicia Tosoni

series ordinal

2

1 reference

19 August 2017

Eugenio Pozzati

series ordinal

3

1 reference

19 August 2017

publication date

1 November 2008

1 reference

Expert Review of Anticancer Therapy

19 August 2017

published in

1 reference

19 August 2017

volume

8

1 reference

19 August 2017

issue

11

1 reference

19 August 2017

page(s)

1781-1786

1 reference

Gene silencing in cancer in association with promoter hypermethylation

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1781

Non-CpG methylation is prevalent in embryonic stem cells and may be mediated by DNA methyltransferase 3a.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1781

Loss of pericentromeric DNA methylation pattern in human glioblastoma is associated with altered DNA methyltransferases expression and involves the stem cell compartment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1781

Genome-wide hypomethylation in human glioblastomas associated with specific copy number alteration, methylenetetrahydrofolate reductase allele status, and increased proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1781

Distinct methylation profiles of glioma subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1781

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1781

DNA alkylation by the haloethylnitrosoureas: nature of modifications produced and their enzymatic repair or removal

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1781

Intracellular Localization and intercellular heterogeneity of the human DNA repair protein O(6)-methylguanine-DNA methyltransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1781

Methylation of discrete regions of the O6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1781

Temozolomide preferentially depletes cancer stem cells in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1781

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1781

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1781

Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1781

Methylguanine methyltransferase testing in glioblastoma: when and how?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1781

Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1781

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1781

MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1781

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1781

Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1781

Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1781

Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1781

Brain radiation lesions: MR imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1781

Prognostic value of detecting recurrent glioblastoma multiforme in surgical specimens from patients after radiotherapy: should pathology evaluation alter treatment decisions?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1781

Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1781

Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.11.1781

10.1586/14737140.8.11.1781

21 January 2018

Identifiers

DOI

1 reference

19 August 2017

1 reference